Synthesis and biological evolution of aryl quinolin-benzimidazole-1,2,3-triazole as anticancer agents

ABSTRACT
A new series of aryl quinolin-benzimidazole-1,2,3-triazole (11a-j) compounds were designed and synthesized and their structures were determined using 1HNMR, 13CNMR, and mass spectral
data. Furthermore, compounds (11a-j) were tested for preliminary anticancer effects on four human cancer cell lines: SiHa (cervix cancer), A549 (lung cancer), MCF-7 (breast cancer), and Colo-205 (colon cancer), with etoposide serving as a positive control. The majority of the de�rivatives had moderate to high activity. Four of them (11a, 11b, 11c, and 11d) showed the most promising activities as positive controls. Particularly, the 3,4,5-trimethoxy substituted compound 11a SiHa=0.012±0.0054 µM; A549=0.043±0.007 µM; MCF-7 = 0.19±0.039 µM and Colo�205=0.11±0.058 µM) exhibits excellent anticancer activity